Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect

<h4>Background</h4> Endogenous ouabain (EO) and atrial natriuretic peptide (ANP) are important in regulation of sodium and fluid balance. There is indirect evidence that ANP may be involved in the regulation of endogenous cardenolides. <h4>Methods</h4> H295R are human adrenoc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gulay Tegin, Yonglin Gao, John M. Hamlyn, Barbara J. Clark, Rif S. El-Mallakh
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/018131678c4d49269d480a0d25e6321e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:018131678c4d49269d480a0d25e6321e
record_format dspace
spelling oai:doaj.org-article:018131678c4d49269d480a0d25e6321e2021-11-25T06:19:44ZInhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect1932-6203https://doaj.org/article/018131678c4d49269d480a0d25e6321e2021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601428/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4> Endogenous ouabain (EO) and atrial natriuretic peptide (ANP) are important in regulation of sodium and fluid balance. There is indirect evidence that ANP may be involved in the regulation of endogenous cardenolides. <h4>Methods</h4> H295R are human adrenocortical cells known to release EO. Cells were treated with ANP at physiologic concentrations or vehicle (0.1% DMSO), with or without guanylyl cyclase inhibitor 1,2,4 oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). Cyclic guanosine monophosphate (cGMP), the intracellular second messenger of ANP, was measured by a chemiluminescent immunoassay and EO was measured by radioimmunoassay of C18 extracted samples. <h4>Results</h4> EO secretion is inhibited by ANP treatment, with the most prolonged inhibition (90 min vs ≤ 60 min) occurring at physiologic ANP concentrations (50 pg/mL). Inhibition of guanylyl cyclase with ODQ, also reduces EO secretion. The inhibitory effects on EO release in response to cotreatment with ANP and ODQ appeared to be additive. <h4>Conclusions</h4> ANP inhibits basal EO secretion, and it is unlikely that this is mediated through ANP-A or ANP-B receptors (the most common natriuretic peptide receptors) or their cGMP second messenger; the underlying mechanisms involved are not revealed in the current studies. The role of ANP in the control of EO synthesis and secretion in vivo requires further investigation.Gulay TeginYonglin GaoJohn M. HamlynBarbara J. ClarkRif S. El-MallakhPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Gulay Tegin
Yonglin Gao
John M. Hamlyn
Barbara J. Clark
Rif S. El-Mallakh
Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect
description <h4>Background</h4> Endogenous ouabain (EO) and atrial natriuretic peptide (ANP) are important in regulation of sodium and fluid balance. There is indirect evidence that ANP may be involved in the regulation of endogenous cardenolides. <h4>Methods</h4> H295R are human adrenocortical cells known to release EO. Cells were treated with ANP at physiologic concentrations or vehicle (0.1% DMSO), with or without guanylyl cyclase inhibitor 1,2,4 oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). Cyclic guanosine monophosphate (cGMP), the intracellular second messenger of ANP, was measured by a chemiluminescent immunoassay and EO was measured by radioimmunoassay of C18 extracted samples. <h4>Results</h4> EO secretion is inhibited by ANP treatment, with the most prolonged inhibition (90 min vs ≤ 60 min) occurring at physiologic ANP concentrations (50 pg/mL). Inhibition of guanylyl cyclase with ODQ, also reduces EO secretion. The inhibitory effects on EO release in response to cotreatment with ANP and ODQ appeared to be additive. <h4>Conclusions</h4> ANP inhibits basal EO secretion, and it is unlikely that this is mediated through ANP-A or ANP-B receptors (the most common natriuretic peptide receptors) or their cGMP second messenger; the underlying mechanisms involved are not revealed in the current studies. The role of ANP in the control of EO synthesis and secretion in vivo requires further investigation.
format article
author Gulay Tegin
Yonglin Gao
John M. Hamlyn
Barbara J. Clark
Rif S. El-Mallakh
author_facet Gulay Tegin
Yonglin Gao
John M. Hamlyn
Barbara J. Clark
Rif S. El-Mallakh
author_sort Gulay Tegin
title Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect
title_short Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect
title_full Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect
title_fullStr Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect
title_full_unstemmed Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect
title_sort inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/018131678c4d49269d480a0d25e6321e
work_keys_str_mv AT gulaytegin inhibitionofendogenousouabainbyatrialnatriureticpeptideisaguanylylcyclaseindependenteffect
AT yonglingao inhibitionofendogenousouabainbyatrialnatriureticpeptideisaguanylylcyclaseindependenteffect
AT johnmhamlyn inhibitionofendogenousouabainbyatrialnatriureticpeptideisaguanylylcyclaseindependenteffect
AT barbarajclark inhibitionofendogenousouabainbyatrialnatriureticpeptideisaguanylylcyclaseindependenteffect
AT rifselmallakh inhibitionofendogenousouabainbyatrialnatriureticpeptideisaguanylylcyclaseindependenteffect
_version_ 1718413842791268352